Although there is limited research on the use of valproic acid [78] and MMS [79] in PD therapy, our molecular docking analysis revealed that valproic acid forms hydrogen bonds with SUMO3 residues LYS-544 and ASP-580, as well as with SEH1L residues PHE-227 and SER-169. The gene discussed is SEH1L; the disease is Parkinson disease.